Logo
x

Search

Subscribe Now

gsk

GSK Highlights Full Results from the P-III (SWIFT-1 and SWIFT-2) Trials of Depemokimab for Treating Severe Asthma at ERS 2024

GSK Highlights Full Results from the P-III (SWIFT-1 and SWIFT-2) Trials of Depemokimab for Treating Severe Asthma at ERS 2024

  • September 10, 2024
GSK Reports the P-III Study Results of Nucala (Mepolizumab) for Treating Chronic Obstructive Pulmonary Disease (COPD)

GSK Reports the P-III Study Results of Nucala (Mepolizumab) for Treating Chronic Obstructive Pulmonary Disease (COPD)

  • September 6, 2024
GSK’s Arexvy Vaccine Receives the EC’s Approval for its Expanded Age Indication to Prevent Lower Respiratory Tract Disease (LRTD)

GSK’s Arexvy Vaccine Receives the EC’s Approval for its Expanded Age Indication to Prevent Lower Respiratory Tract Disease (LRTD)

  • August 29, 2024
GSK’s Nucala (Mepolizumab) Receives Japanese Approval for Treating Chronic Rhinosinusitis with Nasal Polyps

GSK’s Nucala (Mepolizumab) Receives Japanese Approval for Treating Chronic Rhinosinusitis with Nasal Polyps

  • August 28, 2024
GSK’s GSK5764227 (GSK’227) Gets the US FDA’s Breakthrough Therapy Designation for r/r Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

GSK’s GSK5764227 (GSK’227) Gets the US FDA’s Breakthrough Therapy Designation for r/r Extensive-Stage Small-Cell Lung Cancer (ES-S...

  • August 20, 2024
GSK Reports the US FDA’s Expanded Approval of Jemperli Plus Chemotherapy for Treating Endometrial Cancer

GSK Reports the US FDA’s Expanded Approval of Jemperli Plus Chemotherapy for Treating Endometrial Cancer

  • August 2, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.